Päivi Polo-Kantola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Päivi Polo-Kantola has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Olli Polo
Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland
7 shared publicationsRisto Erkkola
Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland
7 shared publicationsKerttu Irjala
Sleep Research Unit, Department of Physiology, and Departments of Biostatistics, University of Turku, Turku, Finland; Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland; Mehilainen Oy, Turku, Finland; Department of Physiology, University of Helsinki, Finland; and Department of Pulmonary Diseases, Tampere University Hospital, Tampere, Finland
6 shared publicationsEsa Rauhala
Department of Clinical Neurophysiology, Satakunta Central Hospital, Pori, Finland
4 shared publicationsHans Helenius
Department of Physiology and Biostatistics, University of Turku, Turku, Finland
2 shared publicationsSirkku Pullinen
Department of Obstetrics and Gynecology, Turku University Central Hospital, Turku, Finland
2 shared publications
Latest Publications
- 1 October 2008
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 63 (10) , 640-641
24-Hour Serum Levels of Growth Hormone, Prolactin, and Cortisol in Pre- and Postmenopausal Women: The Effect of Combined Estrogen and Progestin Treatment
Previous studies of the effects of hormone therapy (HT) on levels of growth hormone (GH), prolactin (PRL), and cortisol have yielded conflicting results. The present study analyzed 24-hour profiles of these hormones before and after estrogen/progestin treatment (EPT) in 17 healthy premenopausal women 45 to 51 years of age and 18 postmenopausal women 58 to 70 years of age. Using a randomized, placebo-controlled, double-blind design, hormone levels were sampled at 20-minute intervals for 24 hours, before and after 6 months of EPT. Premenopausal women received cyclic EPT with 2 mg of estradiol valerate for 16 days, followed by estradiol plus 1 mg of norethisterone acetate (NETA) for 12 days. Postmenopausal women received continuous EPT with 2 mg of estradiol valerate plus 0.7 mg of NETA. Some women in each of these groups received placebo. Mean 24-hour levels of both GH and PRL were lower in postmenopausal than in premenopausal women. Average serum concentrations were 1.0 versus 1.8 mU/L, respectively, for 24-hour GH, and 6.8 versus 10.0 ng/ml for PRL. No such difference was found for either GH or PRL following EPT, at which time baseline hormone levels were comparable in pre and postmenopausal women. Mean postmenopausal 24-hour levels of GH and PRL were higher during EPT than in control subjects, as were daytime GH levels and nighttime PRL concentrations. No differences in serum cortisol were observed. In premenopausal women, mean nighttime PRL and cortisol levels were higher during EPT than in placebo recipients. Postmenopausal PRL levels and premenopausal levels of GH and PRL were higher at night than during the day, whether or not subjects were receiving EPT.
- 1 October 2008
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 63 (10) , 640-641
24-Hour Serum Levels of Growth Hormone, Prolactin, and Cortisol in Pre- and Postmenopausal Women: The Effect of Combined Estrogen and Progestin Treatment
Previous studies of the effects of hormone therapy (HT) on levels of growth hormone (GH), prolactin (PRL), and cortisol have yielded conflicting results. The present study analyzed 24-hour profiles of these hormones before and after estrogen/progestin treatment (EPT) in 17 healthy premenopausal women 45 to 51 years of age and 18 postmenopausal women 58 to 70 years of age. Using a randomized, placebo-controlled, double-blind design, hormone levels were sampled at 20-minute intervals for 24 hours, before and after 6 months of EPT. Premenopausal women received cyclic EPT with 2 mg of estradiol valerate for 16 days, followed by estradiol plus 1 mg of norethisterone acetate (NETA) for 12 days. Postmenopausal women received continuous EPT with 2 mg of estradiol valerate plus 0.7 mg of NETA. Some women in each of these groups received placebo. Mean 24-hour levels of both GH and PRL were lower in postmenopausal than in premenopausal women. Average serum concentrations were 1.0 versus 1.8 mU/L, respectively, for 24-hour GH, and 6.8 versus 10.0 ng/ml for PRL. No such difference was found for either GH or PRL following EPT, at which time baseline hormone levels were comparable in pre and postmenopausal women. Mean postmenopausal 24-hour levels of GH and PRL were higher during EPT than in control subjects, as were daytime GH levels and nighttime PRL concentrations. No differences in serum cortisol were observed. In premenopausal women, mean nighttime PRL and cortisol levels were higher during EPT than in placebo recipients. Postmenopausal PRL levels and premenopausal levels of GH and PRL were higher at night than during the day, whether or not subjects were receiving EPT.
- Open Access
- 1 January 2007
- Published by SAGE Publications in Women's Health
- Vol. 3 (1) , 99-106
Sleep and Menopause
Sleeping problems are a serious public health problem, imposing a substantial burden on individuals and society. Although sleeping problems occur throughout the lifespan, and in both sexes, menopause can be considered as one important milestone of increasing occurrence in sleeping problems. However, to determine whether sleeping problems are caused by the menopause or merely occur by coincidence during the menopause is not always easy because several, particularly age-related, changes take place at the same time. The most important factors are general diseases, medications, weight changes and mood symptoms. According to women's own judgment, hormone therapy significantly improves sleep quality. Hormone therapy can thus be considered as a first-line treatment for climacteric sleeping problems. If sleeping problems are accompanied by other disorders, hormone therapy should be kept in mind as an adjuvant therapy. According to worldwide consensus on hormone therapy, the main indication of hormone therapy is alleviation of climacteric symptoms, including climacteric sleeping problems. However, when choosing hormone therapy for a patient, contraindications and possible long-term side effects should be individually considered. This review illustrates the effect of menopause on sleep and evaluates different treatment options, especially hormone therapy, in alleviation of symptoms.
- 1 January 2007
- Published by SAGE Publications in Women's Health
- Vol. 3 (1) , 99-106
Open AccessSleep and Menopause
Sleeping problems are a serious public health problem, imposing a substantial burden on individuals and society. Although sleeping problems occur throughout the lifespan, and in both sexes, menopause can be considered as one important milestone of increasing occurrence in sleeping problems. However, to determine whether sleeping problems are caused by the menopause or merely occur by coincidence during the menopause is not always easy because several, particularly age-related, changes take place at the same time. The most important factors are general diseases, medications, weight changes and mood symptoms. According to women's own judgment, hormone therapy significantly improves sleep quality. Hormone therapy can thus be considered as a first-line treatment for climacteric sleeping problems. If sleeping problems are accompanied by other disorders, hormone therapy should be kept in mind as an adjuvant therapy. According to worldwide consensus on hormone therapy, the main indication of hormone therapy is alleviation of climacteric symptoms, including climacteric sleeping problems. However, when choosing hormone therapy for a patient, contraindications and possible long-term side effects should be individually considered. This review illustrates the effect of menopause on sleep and evaluates different treatment options, especially hormone therapy, in alleviation of symptoms.
- 1 July 2003
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 102 (1) , 68-75
Breathing during sleep in menopause a randomized, controlled, crossover trial with estrogen therapy
To evaluate the prevalence of different types of nocturnal breathing abnormalities in postmenopausal women and the effect of estrogen replacement therapy (ERT) on nocturnal breathing. A prospective, randomized, placebo-controlled, double-blind, crossover study was completed by 62 of 71 recruited healthy women. The first 3-month treatment period with either estrogen or placebo was followed by placebo washout for a month and then by a second treatment period with crossover to either estrogen or placebo. On a night after each treatment period, sleep was monitored with polysomnography, and breathing was assessed with a static-charge-sensitive bed and oximeter. For the respiratory variables, a sample size of 48 subjects was sufficient to give statistical power of 85% with a significance level of P < .05. The occurrence of obstructive sleep apnea in all women was low (1.6%), but partial upper airway obstruction, manifesting as an increased respiratory resistance pattern, was more common (17.7%). Estrogen replacement therapy decreased the occurrence (P = .047) and frequency (P = .049) of sleep apnea but had no effect on partial upper airway obstruction or arterial oxyhemoglobin saturation. Partial upper airway obstruction is the most prevalent form of sleep-disordered breathing, occurring ten times more frequently than sleep apnea in postmenopausal women. Unopposed estrogen replacement therapy has only a minor effect on sleep apnea and has no effect on partial airway obstruction.
- 1 July 2003
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 102 (1) , 68-75
Breathing during sleep in menopause a randomized, controlled, crossover trial with estrogen therapy
To evaluate the prevalence of different types of nocturnal breathing abnormalities in postmenopausal women and the effect of estrogen replacement therapy (ERT) on nocturnal breathing. A prospective, randomized, placebo-controlled, double-blind, crossover study was completed by 62 of 71 recruited healthy women. The first 3-month treatment period with either estrogen or placebo was followed by placebo washout for a month and then by a second treatment period with crossover to either estrogen or placebo. On a night after each treatment period, sleep was monitored with polysomnography, and breathing was assessed with a static-charge-sensitive bed and oximeter. For the respiratory variables, a sample size of 48 subjects was sufficient to give statistical power of 85% with a significance level of P < .05. The occurrence of obstructive sleep apnea in all women was low (1.6%), but partial upper airway obstruction, manifesting as an increased respiratory resistance pattern, was more common (17.7%). Estrogen replacement therapy decreased the occurrence (P = .047) and frequency (P = .049) of sleep apnea but had no effect on partial upper airway obstruction or arterial oxyhemoglobin saturation. Partial upper airway obstruction is the most prevalent form of sleep-disordered breathing, occurring ten times more frequently than sleep apnea in postmenopausal women. Unopposed estrogen replacement therapy has only a minor effect on sleep apnea and has no effect on partial airway obstruction.
- 1 January 2003
- Vol. 119 (22) , 2207-14
[Neuropause?].
- Open Access
- 1 August 2001
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 80 (8) , 679-682
Alzheimer’s disease and estrogen replacement therapy – where are we now?
- 1 August 2001
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 80 (8) , 679-682
Open AccessAlzheimer’s disease and estrogen replacement therapy – where are we now?
- 1 April 2001
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 97 (4) , 548-554
Estrogen Replacement Therapy and Nocturnal Periodic Limb Movements
Objective To evaluate the effect of estrogen replacement therapy on nocturnal periodic limb movements in a randomized, double-masked, placebo-controlled, crossover trial. Methods Seventy-one healthy postmenopausal women volunteered in answer to a newspaper announcement; 62 women completed the follow-up. Frequency of nocturnal body movements was measured with the static-charge-sensitive bed and all-night polysomnographic recordings. Serum estradiol (E2) and FSH concentrations were also measured at baseline and after each treatment period. The power of the study setup was 94%. Results Nearly half the women presented with episodes of periodic limb movements (30 of 62 women, or 48%, during placebo and 27, or 44%, during estrogen therapy). In 17 (27%) during placebo and 19 (31%) during estrogen therapy, frequency of periodic limb movements exceeded index level 5 per hour while subjects were in bed. Incidence or intensity of movements, movement durations, and movement intervals did not change with estrogen therapy. The arousal index was similar during the two treatments (medians = 1.7 for placebo and 1.3 for estrogen, P = .758). Variations in serum E2 concentration, age, and body mass index did not explain variations in movement activity. Conclusion Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.
- 1 April 2001
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 97 (4) , 548-554
Estrogen Replacement Therapy and Nocturnal Periodic Limb Movements
Objective To evaluate the effect of estrogen replacement therapy on nocturnal periodic limb movements in a randomized, double-masked, placebo-controlled, crossover trial. Methods Seventy-one healthy postmenopausal women volunteered in answer to a newspaper announcement; 62 women completed the follow-up. Frequency of nocturnal body movements was measured with the static-charge-sensitive bed and all-night polysomnographic recordings. Serum estradiol (E2) and FSH concentrations were also measured at baseline and after each treatment period. The power of the study setup was 94%. Results Nearly half the women presented with episodes of periodic limb movements (30 of 62 women, or 48%, during placebo and 27, or 44%, during estrogen therapy). In 17 (27%) during placebo and 19 (31%) during estrogen therapy, frequency of periodic limb movements exceeded index level 5 per hour while subjects were in bed. Incidence or intensity of movements, movement durations, and movement intervals did not change with estrogen therapy. The arousal index was similar during the two treatments (medians = 1.7 for placebo and 1.3 for estrogen, P = .758). Variations in serum E2 concentration, age, and body mass index did not explain variations in movement activity. Conclusion Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.
- 1 April 2001
- Published by Wolters Kluwer Health
- Vol. 97 (4) , 548-554
Estrogen replacement therapy and nocturnal periodic limb movements: A randomized controlled trial
Objective: To evaluate the effect of estrogen replacement therapy on nocturnal periodic limb movements in a randomized, double-masked, placebo-controlled, crossover trial. Methods: Seventy-one healthy postmenopausal women volunteered in answer to a newspaper announcement; 62 women completed the follow-up. Frequency of nocturnal body movements was measured with the static-charge-sensitive bed and all-night polysomnographic recordings. Serum estradiol (E2) and FSH concentrations were also measured at baseline and after each treatment period. The power of the study setup was 94%. Results: Nearly half the women presented with episodes of periodic limb movements (30 of 62 women, or 48%, during placebo and 27, or 44%, during estrogen therapy). In 17 (27%) during placebo and 19 (31%) during estrogen therapy, frequency of periodic limb movements exceeded index level 5 per hour while subjects were in bed. Incidence or intensity of movements, movement durations, and movement intervals did not change with estrogen therapy. The arousal index was similar during the two treatments (medians = 1.7 for placebo and 1.3 for estrogen, P = .758). Variations in serum E2 concentration, age, and body mass index did not explain variations in movement activity. Conclusion: Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.
- 1 April 2001
- Published by Wolters Kluwer Health
- Vol. 97 (4) , 548-554
Estrogen replacement therapy and nocturnal periodic limb movements: A randomized controlled trial
Objective: To evaluate the effect of estrogen replacement therapy on nocturnal periodic limb movements in a randomized, double-masked, placebo-controlled, crossover trial. Methods: Seventy-one healthy postmenopausal women volunteered in answer to a newspaper announcement; 62 women completed the follow-up. Frequency of nocturnal body movements was measured with the static-charge-sensitive bed and all-night polysomnographic recordings. Serum estradiol (E2) and FSH concentrations were also measured at baseline and after each treatment period. The power of the study setup was 94%. Results: Nearly half the women presented with episodes of periodic limb movements (30 of 62 women, or 48%, during placebo and 27, or 44%, during estrogen therapy). In 17 (27%) during placebo and 19 (31%) during estrogen therapy, frequency of periodic limb movements exceeded index level 5 per hour while subjects were in bed. Incidence or intensity of movements, movement durations, and movement intervals did not change with estrogen therapy. The arousal index was similar during the two treatments (medians = 1.7 for placebo and 1.3 for estrogen, P = .758). Variations in serum E2 concentration, age, and body mass index did not explain variations in movement activity. Conclusion: Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.
- 1 January 2001
- Published by Springer Nature in CNS Drugs
- Vol. 15 (6) , 445-452
Aetiology and Treatment of Sleep Disturbances During Perimenopause and Postmenopause
The sudden and predictable cessation of ovarian endocrinological function at menopause results in a marked decrease of endogenous estrogen and progestogen secretion. In addition to cessation of menstruation, a wide range of biological functions, including sleep, are affected. Sleep disturbances are more common in women than in men and their incidence increases with age. There are 2 distinct mechanisms by which menopause is known to affect sleep quality. One is menopausal insomnia, which can be considered as part of the symptomatology of the climacterium. Another is sleep-disordered breathing, where impairment of sleep quality is secondary to sleep apnoea or partial upper airway obstruction during sleep. The former is effectively controlled with conventional estrogen replacement therapy, whereas the latter could potentially be improved with progestogens. Many age-related conditions without a direct link with the menopause should also be considered when treating postmenopausal sleep disorders.
- 1 January 2001
- Published by Springer Nature in CNS Drugs
- Vol. 15 (6) , 445-452
Aetiology and Treatment of Sleep Disturbances During Perimenopause and Postmenopause
The sudden and predictable cessation of ovarian endocrinological function at menopause results in a marked decrease of endogenous estrogen and progestogen secretion. In addition to cessation of menstruation, a wide range of biological functions, including sleep, are affected. Sleep disturbances are more common in women than in men and their incidence increases with age. There are 2 distinct mechanisms by which menopause is known to affect sleep quality. One is menopausal insomnia, which can be considered as part of the symptomatology of the climacterium. Another is sleep-disordered breathing, where impairment of sleep quality is secondary to sleep apnoea or partial upper airway obstruction during sleep. The former is effectively controlled with conventional estrogen replacement therapy, whereas the latter could potentially be improved with progestogens. Many age-related conditions without a direct link with the menopause should also be considered when treating postmenopausal sleep disorders.
- 1 January 2000
- Vol. 116 (16) , 1689-95
[Estrogen and sleep].